What are the precautions for Inluriyo (Imlunestrant)?

Inluriyo (Imlunestrant) is a selective estrogen receptor degrader, used to treat patients with ER-positive, HER2-negative advanced or metastatic breast cancer carrying ESR1 mutations. During use, safety precautions must be strictly followed to reduce potential risks.

First of all, the risk of fetal toxicity during pregnancy and embryo requires special attention. Based on animal studies and the drug's mechanism of action, Inluriyo may cause fetal harm. Increased embryo-fetal mortality and structural malformations were observed in rats treated with the drug during pregnancy, suggesting that the drug may interfere with embryonic development. Although the specific effects in humans have not been fully determined, the drug is hypothesized to have potential reproductive toxicity due to the critical role of the estrogen receptor in embryonic development. Therefore, this drug is contraindicated in pregnant women.

For female patients of childbearing potential, the non-pregnant status should be confirmed before starting treatment, and effective contraceptive measures should be continued duringInluriyo treatment and for at least 1 week after the last dose. Physicians should fully educate patients about potential fetal risks and recommend the use of reliable barrier or hormonal contraception.

At the same time, male patients whose partners have childbearing potential should also use effective contraceptive methods during the entire treatment period and within 1 week after the last dose to prevent potential effects of drug exposure on the embryo.

In addition, all treated patients should be informed that if pregnancy occurs while taking the drug, they should immediately stop taking the drug and notify their doctor to assess the risk and follow-up management options.

Overall,Although Inluriyo is an important advance in the precision treatment of breast cancer, it has clear warnings about reproductive safety. Strict contraceptive management and risk communication are key to ensuring treatment safety.

Reference materials:https://www.drugs.com/inluriyo.html